Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» spinal muscular atrophy
spinal muscular atrophy
Biogen's new Spinraza data for earlier use 'pretty amazing,' analyst says
Fierce Pharma
Mon, 10/8/18 - 11:37 pm
Biogen
Spinraza
spinal muscular atrophy
SMA
Genentech Announces New Data for Risdiplam in Spinal Muscular Atrophy in Infants
CP Wire
Wed, 10/3/18 - 09:33 am
Genentech/Roche
risdiplam
spinal muscular atrophy
Genentech Announces New Data for Risdiplam in Spinal Muscular Atrophy in Infants
Wed, 10/3/18 - 09:33 am
Genentech/Roche
risdiplam
spinal muscular atrophy
[video+transcript]Gene Therapy Could Be a Boon for This Biotech
Motley Fool
Sun, 09/30/18 - 03:38 pm
gene therapy
Rengexbio
spinal muscular atrophy
wet age-related macular degeneration
Biogen's Spinraza gets an early no-go from NICE
Biopharma Dive
Wed, 08/15/18 - 09:57 am
Biogen
UK
NICE
Spinraza
SMA
spinal muscular atrophy
Why PTC Therapeutics Dropped 30.6% Today After Jumping 27.5% Yesterday
Motley Fool
Tue, 06/19/18 - 10:42 pm
PTC Therapeutics
risdiplam
Biogen
Ionis Pharmaceuticals
spinal muscular atrophy
Sarepta Therapeutics
Translarna
Emflaza
After a crushing PhIII failure, Cytokinetics says its next-gen muscle drug is lining up well in PhII — but big challenges loom
Endpoints
Mon, 06/18/18 - 10:00 am
Cytokinetics
clinical trials
reldesemtiv
Tirasemtiv
spinal muscular atrophy
Astellas
Roche scraps €120M SMA drug after hitting ‘many difficulties’
Fierce Biotech
Fri, 06/1/18 - 11:25 pm
Roche
SMA
spinal muscular atrophy
Olesoxime
Biogen’s Spinraza Sales Slow as AveXis and Novartis Pursue SMA Gene Therapy
Xtalks
Fri, 04/27/18 - 10:03 am
Biogen
earnings
Spinraza
spinal muscular atrophy
First Patient Dosed in Avexis' Phase 3 Trial of AVXS-101 in Pre-Symptomatic Spinal Muscular Atrophy
CP Wire
Wed, 04/25/18 - 10:29 pm
AveXis
Novartis
M&A
clinical trials
AVXS-101
gene therapy
spinal muscular atrophy
Novartis buying AveXis for $8.7 billion to strengthen gene therapy capabilities
Stat
Mon, 04/9/18 - 09:00 am
Novartis
M&A
AveXis
gene therapy
AVXS-101
SMA
spinal muscular atrophy
Biogen Unlikely To See Spinraza Rival In 2018 As AveXis Delayed
Investors Business Daily
Fri, 01/5/18 - 05:44 pm
Biogen
Spinraza
AveXis
AVXS-101
spinal muscular atrophy
NEJM publishes Phase III results for Biogen/Ionis’ Spinraza
GoinPharma
Mon, 11/6/17 - 08:56 am
Biogen
Ionis Pharmaceuticals
Spinraza
clinical trials
spinal muscular atrophy
SMA
US Spinraza sales cause concern among Biogen investors
Biopharma Dive
Wed, 10/25/17 - 09:40 am
Biogen
Spinraza
spinal muscular atrophy
investors
Spinraza launch set for blockbuster trajectory
BioPharma Dive
Wed, 07/26/17 - 12:11 am
Spinraza
Biogen
SMA
spinal muscular atrophy
For Biogen's Spinraza launch, things are looking up on the coverage front: analyst
Fierce Pharma
Thu, 07/20/17 - 10:11 am
Biogen
Spinraza
drug launches
spinal muscular atrophy
SMA
PTC and Roche report solid data for Spinraza rival
BioPharma Dive
Wed, 07/5/17 - 06:55 pm
PTC Therapeutics
Roche
Spinraza
Biogen
RG7916
SMA
spinal muscular atrophy
Biogen’s Spinraza Witnessed Robust Patient Demand in 1Q17
Market Realist
Fri, 04/28/17 - 11:45 am
Biogen
Spinraza
patients
SMA
spinal muscular atrophy
Hyde Park boy with rare disease wins appeal, will receive Biogen drug
Bizjournals.com
Wed, 04/26/17 - 09:35 pm
Biogen
Spinraza
SMA
spinal muscular atrophy
Biogen touts stronger-than-expected rollout for Spinraza
BioPharma Dive
Wed, 04/26/17 - 10:58 am
Biogen
Spinraza
drug launches
SMA
spinal muscular atrophy
Pages
« first
‹ previous
1
2
3
4
5
next ›
last »